63 related articles for article (PubMed ID: 25397567)
21. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.
Gärtner K; Domínguez-Rodríguez S; Heaney J; Gkouleli T; Grant P; Dorgham K; Sauce D; Soulie C; Busby EJ; O'Sullivan DM; Spyer M; Botha JC; Muñoz-Fernandez MA; Tagarro A; Cotugno N; Huggett JF; Klein N; Palma P; Rojo Conejo P; Foster C; Giaquinto C; Rossi P; Persaud D; De Rossi A; Marcelin AG; Nastouli E
Front Immunol; 2024; 15():1334236. PubMed ID: 38444847
[TBL] [Abstract][Full Text] [Related]
22. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
[TBL] [Abstract][Full Text] [Related]
23. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
Haïm-Boukobza S; Morand-Joubert L; Flandre P; Valin N; Fourati S; Sayon S; Lavignon M; Simon A; Girard PM; Katlama C; Calvez V; Marcelin AG
AIDS; 2011 Jan; 25(3):341-4. PubMed ID: 21157295
[TBL] [Abstract][Full Text] [Related]
24. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
25. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
Chimsuntorn S; Sungkanuparph S; Manosuthi W
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):43-5. PubMed ID: 20071597
[TBL] [Abstract][Full Text] [Related]
26. Hypovitaminosis D in HIV-infected patients in Lisbon: a link with antiretroviral treatment.
Boura M; Sutre AF; Badura R; Zagalo A; Afonso C; Caldeira L; Valadas E
J Int AIDS Soc; 2014; 17(4 Suppl 3):19826. PubMed ID: 25397570
[TBL] [Abstract][Full Text] [Related]
27. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
[TBL] [Abstract][Full Text] [Related]
28. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
30. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
31. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
[TBL] [Abstract][Full Text] [Related]
32. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
34. Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study.
Leierer G; Rieger A; Steuer A; Sarcletti M; Geit M; Haas B; Taylor N; Kanatschnig M; Rappold M; Ledergerber B; Zangerle R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19667. PubMed ID: 25397417
[TBL] [Abstract][Full Text] [Related]
35. Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matter.
Erdbeer G; Sabranski M; Sonntag I; Stoehr A; Horst HA; Plettenberg A; Schewe K; Unger S; Stellbrink HJ; Fenske S; Hoffmann C
J Int AIDS Soc; 2014; 17(4 Suppl 3):19689. PubMed ID: 25397439
[TBL] [Abstract][Full Text] [Related]
36. Accurate episomal HIV 2-LTR circles quantification using optimized DNA isolation and droplet digital PCR.
Malatinkova E; Kiselinova M; Bonczkowski P; Trypsteen W; Messiaen P; Vermeire J; Verhasselt B; Vervisch K; Vandekerckhove L; De Spiegelaere W
J Int AIDS Soc; 2014; 17(4 Suppl 3):19674. PubMed ID: 25397424
[TBL] [Abstract][Full Text] [Related]
37. Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL.
Dentone C; Fenoglio D; Signori A; Cenderello G; Parodi A; Bozzano F; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Kalli F; Marras F; Fraccaro P; Giacomini M; Cassola G; Bruzzone B; Ferrea G; Viscoli C; Filaci G; De Maria A; Di Biagio A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19718. PubMed ID: 25397464
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 RNA monitoring with a dual-target diagnostic assay: A case report.
Sberna G; Gagliardini R; Rozera G; Forbici F; Cicalini S; Antinori A; Maggi F; Amendola A
Heliyon; 2024 May; 10(9):e29842. PubMed ID: 38699019
[TBL] [Abstract][Full Text] [Related]
39. Sex Differences in CMV Replication and HIV Persistence During Suppressive ART.
Gianella S; Tran SM; Morris S; Vargas M; Porrachia M; Oliveira MF; Lada S; Zhao M; Ellsworth GB; Mathad JS; Wilkin T
Open Forum Infect Dis; 2020 Aug; 7(8):ofaa289. PubMed ID: 32793766
[TBL] [Abstract][Full Text] [Related]
40. Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy.
Rassler S; Ramirez R; Khoury N; Skowron G; Sahu GK
Virol J; 2016 Sep; 13(1):157. PubMed ID: 27655142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
